AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31854365 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival control (Supra) plus scaling and root planing (SRP) on Day 0
Number of subjects: 25
Study 31854365 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival control (Supra) on Day 0 and SRP 30 days later
Number of subjects: 25
Study 31854365 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 25
Study 29318859 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao acupuncture combined with hyperbaric oxygen
Number of subjects: 40
Study 29318859 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen only
Number of subjects: 40
Study 26928753 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-AzeFlu
Number of subjects: 348
Study 26928753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 24982456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and folinic acid-modulated fluorouracil (OFF)
Number of subjects: 168
Study 24982456 — intervention group
Group type: COMPARATOR
Intervention: Folinic acid and fluorouracil (FF)
Number of subjects: 168
Study 22805286 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea polyphenols (GTP) 640 mg
Number of subjects: 16
Study 22805286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19769480 — intervention group
Group type: EXPERIMENTAL
Intervention: Menoprogen (0.2 g extracts of five herbs per capsule, two capsules orally, twice daily)
Number of subjects: 0
Study 19769480 — intervention group
Group type: EXPERIMENTAL
Intervention: Menoprogen
Number of subjects: 0
Study 17369516 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-focused training for 2 weeks
Number of subjects: 4
Study 15345867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-modified diet (SFA < 10%, MUFA 10-5%, PUFA up to 10%, cholesterol < 300 mg/day)
Number of subjects: 180
Study 11393673 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg/day
Number of subjects: 30
Study 11393673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9729372 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine therapy
Number of subjects: 3
Study 9065130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Number of subjects: 30
Study 9065130 — intervention group
Group type: COMPARATOR
Intervention: Intravenous promethazine
Number of subjects: 30
Study 2680157 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 468
Study 2680157 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 468
Study 2680157 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (type 1)
Number of subjects: 468
Study 2680157 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (type 1)
Number of subjects: 468
Study 2680157 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (type 2)
Number of subjects: 468
Study 2680157 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (type 2)
Number of subjects: 468
Study 2680157 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (lowest ejection fraction tercile)
Number of subjects: 468
Study 2680157 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (lowest ejection fraction tercile)
Number of subjects: 468
Study 132142 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoic acid
Number of subjects: 211
Study 132142 — intervention group
Group type: COMPARATOR
Intervention: Sulfur-resorcinol-salicylic acid
Number of subjects: 211
Study 132142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 31219052 — intervention group
Group type: COMPARATOR
Intervention: Web-based smoking intervention for smokers with no ADS
Number of subjects: 2512
Study 31219052 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking intervention for smokers with depression
Number of subjects: 2512
Study 31219052 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking intervention for smokers with PTSD
Number of subjects: 2512
Study 31219052 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking intervention for smokers with panic disorder
Number of subjects: 2512
Study 31219052 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking intervention for smokers with two or more ADS
Number of subjects: 2512
Study 28572626 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing pyjamas
Number of subjects: 30
Study 28572626 — intervention group
Group type: COMPARATOR
Intervention: Wearing day clothes
Number of subjects: 30
Study 26046102 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Bifidobacterium lactis (1×10(6) per gram), 200g once daily for 2 weeks
Number of subjects: 49
Study 26046102 — intervention group
Group type: COMPARATOR
Intervention: Normal yogurt, consumed by control group
Number of subjects: 49
Study 23359066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 50
Study 23359066 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 50
Study 22088897 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading an article about the 2009 USPSTF mammogram guidelines
Number of subjects: 249
Study 19325490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (3 doses of 1.5 mg per day starting the evening before surgery until the evening of the sixth postoperative day)
Number of subjects: 120
Study 19325490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19325490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 120
Study 16198451 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pneumococcal conjugate and pneumococcal polysaccharide vaccination
Number of subjects: 0
Study 15448038 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of zoledronic acid
Number of subjects: 74
Study 15448038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11066186 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 123
Study 11066186 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 123
Study 9069483 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warfarin and active aspirin
Number of subjects: 405
Study 9069483 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warfarin and placebo aspirin
Number of subjects: 405
Study 9069483 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo warfarin and active aspirin
Number of subjects: 405
Study 9069483 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 405
Study 8367963 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal violence incidents
Number of subjects: 640
Study 3820942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan membrane with acetate dialysate
Number of subjects: 13
Study 3820942 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrilonitrile membrane (PAN) with acetate dialysate
Number of subjects: 13
Study 3820942 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN with bicarbonate dialysate
Number of subjects: 13
Study 3820942 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysate (control for PCO2)
Number of subjects: 13
Study 31972253 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (n=6)
Number of subjects: 24
Study 31972253 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n=4)
Number of subjects: 24
Study 29929169 — intervention group
Group type: EXPERIMENTAL
Intervention: IV PCA + posterior QLB with 0.3 ml/kg 0.25% bupivacaine
Number of subjects: 60
Study 29929169 — intervention group
Group type: COMPARATOR
Intervention: IV PCA + posterior QLB with 0.3 ml/kg 0.9% saline
Number of subjects: 60
Study 26621483 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study 26621483 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)/azathioprine (AZA)
Number of subjects: 0
Study 24929235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 280
Study 24929235 — intervention group
Group type: COMPARATOR
Intervention: Combination of emtricitabine and TDF (FTC/TDF)
Number of subjects: 280
Study 22415494 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron, folic acid, and cobalamin (Group II)
Number of subjects: 150
Study 22415494 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (Group I)
Number of subjects: 150
Study 20137789 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 22
Study 20137789 — intervention group
Group type: EXPERIMENTAL
Intervention: De-alcoholized red wine
Number of subjects: 22
Study 18930789 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial flow with viewpoint jitter synchronized to lateral head oscillation
Number of subjects: 4
Study 18930789 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial flow with viewpoint jitter viewed by stationary observers
Number of subjects: 4
Study 18930789 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial flow without viewpoint jitter viewed during head oscillation
Number of subjects: 4
Study 18930789 — intervention group
Group type: COMPARATOR
Intervention: Radial flow without viewpoint jitter viewed by stationary observers
Number of subjects: 4
Study 15709999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 435
Study 15709999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 11949767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg
Number of subjects: 15
Study 11949767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg
Number of subjects: 15
Study 11949767 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 3 mg
Number of subjects: 15
Study 11949767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11949767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 15
Study 11949767 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 15
Study 11949767 — intervention group
Group type: EXPERIMENTAL
Intervention: N1/P2 response
Number of subjects: 15
Study 10505032 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 29
Study 10505032 — intervention group
Group type: COMPARATOR
Intervention: Age >= 40 years (poor prognostic variable)
Number of subjects: 29
Study 7753949 — intervention group
Group type: EXPERIMENTAL
Intervention: High-priority instructions
Number of subjects: 0
Study 7753949 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels-of-processing manipulation
Number of subjects: 0
Study 2149042 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin at a dose of 400 mg/d
Number of subjects: 310
Study 2149042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime with teicoplanin
Number of subjects: 310
Study 2149042 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime without teicoplanin
Number of subjects: 310
Study 2149042 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin for Gram-positive Hickman line-associated bacteraemia
Number of subjects: 310
Study 2149042 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 310
Study 82086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1.6 g daily for 6 weeks
Number of subjects: 27
Study 82086 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 27
Study 82086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and placebo
Number of subjects: 27
Study 30112914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 135
Study 30112914 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 31035212 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile telephone supported Collaborative Stepped Care (mCSC)
Number of subjects: 895
Study 31035212 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Collaborative Stepped Care (oCSC)
Number of subjects: 895
Study 28150097 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-mail program to increase CRC screening rates
Number of subjects: 8
Study 28150097 — intervention group
Group type: COMPARATOR
Intervention: Implementation challenges faced by community health centers
Number of subjects: 8
Study 25376433 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-supervision intervention in addition to usual supervision (n = 40)
Number of subjects: 83
Study 25376433 — intervention group
Group type: COMPARATOR
Intervention: Usual supervision (n = 43)
Number of subjects: 83
Study 23564362 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intramedullary hip nails
Number of subjects: 33
Study 23564362 — intervention group
Group type: COMPARATOR
Intervention: Long intramedullary hip nails
Number of subjects: 33
Study 21807056 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP(5)-IPV-Hib
Number of subjects: 0
Study 21807056 — intervention group
Group type: COMPARATOR
Intervention: DTaP(3)-IPV/Hib
Number of subjects: 0
Study 21807056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 19127196 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard padded headgear
Number of subjects: 1493
Study 19127196 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified padded headgear
Number of subjects: 1493
Study 19127196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no headgear)
Number of subjects: 1493
Study 16923922 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor
Number of subjects: 10
Study 16923922 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II type 1 receptor antagonist
Number of subjects: 10
Study 16923922 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Angiotensin-converting enzyme inhibitor + Angiotensin II type 1 receptor antagonist)
Number of subjects: 10
Study 15217999 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily from day 3-7 and recombinant FSH (rFSH) 75 IU/day on days 3 and 8
Number of subjects: 38
Study 15217999 — intervention group
Group type: COMPARATOR
Intervention: Long GnRH agonist protocol and stimulated with rFSH (300-450 IU/day)
Number of subjects: 38
Study 11526368 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs) - primarily amiodarone
Number of subjects: 461
Study 9031954 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler umbilical artery velocimetry
Number of subjects: 1903
Study 8497012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour bout of sleep (SB)
Number of subjects: 7
Study 8497012 — intervention group
Group type: COMPARATOR
Intervention: No sleep (Control)
Number of subjects: 7
Study 3306748 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 240 mg
Number of subjects: 8
Study 3306748 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 480 mg
Number of subjects: 8
Study 3306748 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 720 mg
Number of subjects: 8
Study 3306748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28744796 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 (0.1, 0.3, 1, 3, and 10 mg/kg intravenous; 0.3, 1, and 3 mg/kg subcutaneous)
Number of subjects: 79
Study 28744796 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 (1 mg/kg every other week or 0.5-3 mg/kg every week for 8 weeks)
Number of subjects: 79
Study 28744796 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 (1 mg/kg every other week)
Number of subjects: 79
Study 28744796 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 (0.5-3 mg/kg every week)
Number of subjects: 79
Study 28744796 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 (every week dosing)
Number of subjects: 79
Study 28744796 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122
Number of subjects: 79
Study 27053384 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (3 times daily 117 mg or 350 mg/d)
Number of subjects: 52
Study 27053384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25660281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus L-92
Number of subjects: 49
Study 22085840 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-wedge high tibial osteotomy
Number of subjects: 28
Study 20079899 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin (500 mg three times a day) plus simvastatin (20 mg/day)
Number of subjects: 84
Study 20079899 — intervention group
Group type: COMPARATOR
Intervention: metformin (500 mg three times a day) plus placebo
Number of subjects: 84
Study 18462468 — intervention group
Group type: COMPARATOR
Intervention: NTrainer treatment provided to 21 infants.
Number of subjects: 31
Study 18462468 — intervention group
Group type: EXPERIMENTAL
Intervention: NTrainer treatment
Number of subjects: 31
Study 15998657 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (400 IU/day of vitamin E, 500 mg/day of vitamin C, 6 mg/day of beta-carotene)
Number of subjects: 10
Study 15998657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15998657 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 10
Study 14599049 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed milk formula containing fructo- and galacto-oligosaccharides
Number of subjects: 604
Study 10561921 — intervention group
Group type: EXPERIMENTAL
Intervention: ChromaGen haploscopic lenses
Number of subjects: 47
Study 10561921 — intervention group
Group type: COMPARATOR
Intervention: Placebo lenses
Number of subjects: 47
Study 8734674 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily aminoglycosides
Number of subjects: 2317
Study 1885913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction supervised by nursing and medical staff (group 1)
Number of subjects: 151
Study 1885913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction supervised by an experienced respiratory physiotherapist (group 2)
Number of subjects: 151
Study 1885913 — intervention group
Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 151
Study 1885913 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum (adequate samples)
Number of subjects: 151
Study 1885913 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum and BAL
Number of subjects: 151
Study 1885913 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum
Number of subjects: 151
Study 6343340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenoterol 0.8 mg/kg in three divided doses
Number of subjects: 13
Study 6343340 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fenoterol (higher than 0.4 mg three times per day)
Number of subjects: 13
Study 29982562 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted DOACs
Number of subjects: 846
Study 29982562 — intervention group
Group type: COMPARATOR
Intervention: Interrupted DOACs
Number of subjects: 846
Study 28002165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) >14 ng/L and NT-proBNP >300 ng/L
Number of subjects: 572
Study 28002165 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP cutoff at 108 ng/L
Number of subjects: 572
Study 28002165 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 572
Study 28002165 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 572
Study 25770644 — intervention group
Group type: EXPERIMENTAL
Intervention: KETODEX (low-dose ketamine 0.15 mg/kg followed by dexmedetomidine 0.3 μg/kg i.v.)
Number of subjects: 92
Study 25770644 — intervention group
Group type: COMPARATOR
Intervention: Control (volume-matched normal saline)
Number of subjects: 92
Study 24182587 — intervention group
Group type: EXPERIMENTAL
Intervention: RME/FM (Rapid Maxillary Expansion with Facemask)
Number of subjects: 46
Study 24182587 — intervention group
Group type: COMPARATOR
Intervention: BAMP (Bone-Anchored Maxillary Protraction)
Number of subjects: 46
Study 24182587 — intervention group
Group type: EXPERIMENTAL
Intervention: RME/FM
Number of subjects: 46
Study 24182587 — intervention group
Group type: COMPARATOR
Intervention: BAMP
Number of subjects: 46
Study 21923002 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping
Number of subjects: 3
Study 21923002 — intervention group
Group type: COMPARATOR
Intervention: Traditional care planning
Number of subjects: 3
Study 18502089 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 39
Study 17122235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%‐epinephrine (1:200,000)
Number of subjects: 80
Study 17122235 — intervention group
Group type: COMPARATOR
Intervention: Saline‐epinephrine (1:200,000)
Number of subjects: 80
Study 15556955 — intervention group
Group type: COMPARATOR
Intervention: Exercise classes
Number of subjects: 1334
Study 15556955 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulation
Number of subjects: 1334
Study 15556955 — intervention group
Group type: COMPARATOR
Intervention: Manipulation followed by exercise
Number of subjects: 1334
Study 11575892 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 12
Study 11575892 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 12
Study 11575892 — intervention group
Group type: COMPARATOR
Intervention: pMDI plus Nebuhaler
Number of subjects: 12
Study 11575892 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler
Number of subjects: 12
Study 9383927 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Systems Therapy (BFST)
Number of subjects: 0
Study 9383927 — intervention group
Group type: COMPARATOR
Intervention: Education and Support group (ES)
Number of subjects: 0
Study 7953032 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Living Programme (DLP)
Number of subjects: 100
Study 7953032 — intervention group
Group type: COMPARATOR
Intervention: Standard in-patient care
Number of subjects: 100
Study 3435691 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 5
Study 3435691 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 5